OMNI-Ergo-Series
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
March 09, 2023 08:30 ET | Sight Sciences, Inc.
MENLO PARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that...
SightSciences_Logo_2C_RGB.png
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
February 23, 2023 16:05 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
SightSciences_Logo_2C_RGB.png
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
February 22, 2023 16:05 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
SightSciences_Logo_2C_RGB.png
Sight Sciences Announces 1,000th TearCare® Customer Installation
January 26, 2023 08:30 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions...
SightSciences_Logo_2C_RGB.png
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023 16:20 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions...
SightSciences_Logo_2C_RGB.png
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
December 08, 2022 08:30 ET | Sight Sciences, Inc.
DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETINGMEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED BY 44% THROUGH 12 MONTHS MENLO PARK, Calif., Dec. 08, 2022 ...
SightSciences_Logo_2C_RGB.png
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 08:30 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
SightSciences_Logo_2C_RGB.png
Sight Sciences Reports Third Quarter 2022 Financial Results
November 10, 2022 16:05 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
SightSciences_Logo_2C_RGB.png
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
November 03, 2022 08:30 ET | Sight Sciences, Inc.
Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery.Despite glaucoma medications and prior microbypass stenting, target IOP may no...
SightSciences_Logo_2C_RGB.png
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
October 20, 2022 17:20 ET | Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...